

Prof. Dr. med. Andreas Buck

Hänscheid H, Reiners C, Goulko G, Luster M, Schneider-Ludorff M, Buck AK, Lassmann M. Facing the nuclear threat: thyroid blocking revisited. *J Clin Endocrinol Metab.* 2011 Nov;96(11):3511-6. doi: 10.1210/jc.2011-1539. Epub 2011 Aug 24. PMID: 21865356.

Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, Bauer W. 68Ga-DOTATE PET/CT for the detection of inflammation of large arteries: correlation with 18F-FDG, calcium burden and risk factors. *EJNMMI Res.* 2012 Sep 27;2(1):52. doi: 10.1186/2191-219X-2-52. PMID: 23016793; PMCID: PMC3475087.

Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, Reiners C, Samnick SS, Buck AK, Flentje M, Sweeney RA. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. *Radiat Oncol.* 2012 Jun 21;7:99. doi: 10.1186/1748-717X-7-99. PMID: 22720902; PMCID: PMC3439242.

Hänscheid H, Sweeney RA, Flentje M, Buck AK, Löhr M, Samnick S, Kreissl M, Verburg FA. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. *Eur J Nucl Med Mol Imaging.* 2012 Aug;39(8):1284-8. doi: 10.1007/s00259-012-2124-x. Epub 2012 Apr 20. PMID: 22526964.

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C, Allolio B, Schirbel A. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. *J Clin Endocrinol Metab.* 2012 Mar;97(3):914-22. doi: 10.1210/jc.2011-2765. Epub 2011 Dec 14. PMID: 22170726.

Diessl S, Holzberger B, Mäder U, Grelle I, Smit JW, Buck AK, Reiners C, Verburg FA. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. *Clin Endocrinol (Oxf).* 2012 Apr;76(4):586-92. doi: 10.1111/j.1365-2265.2011.04272.x. PMID: 22059804.

Li Z, Herrmann K, Pirsig S, Philipp-Abbrederis K, Henninger M, Aichler M, Feuchtinger A, Walch A, Beer AJ, Ringshausen I, Pomykala KL, Scheidhauer K, Schwaiger M, Keller U, Buck AK. Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. *Am J Nucl Med Mol Imaging.* 2013 Dec 15;4(1):70-9. PMID: 24380047; PMCID: PMC3867731.